The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM

Core Viewpoint - The Gross Law Firm is notifying shareholders of Actinium Pharmaceuticals, Inc. regarding a class action lawsuit due to alleged misleading statements related to the company's drug approval process [1][2]. Summary by Sections Class Action Details - The class period for the lawsuit is from October 31, 2022, to August 2, 2024 [2]. - Allegations include that the company made materially false statements and failed to disclose critical information regarding the Phase 3 Sierra trial data and its implications for FDA approval of the Iomab-B BLA [2]. Allegations Against the Company - The complaint states that the data from the Phase 3 Sierra trial was unlikely to meet FDA guidelines for approval [2]. - Additional analyses provided to the FDA to support the Iomab-B BLA were also unlikely to satisfy the FDA's requirements [2]. - As a result, the FDA was expected to refuse to review the Iomab-B BLA or deny approval if it did consider the application [2]. - The company's positive statements about its business and prospects were deemed materially misleading [2]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by May 27, 2025, to participate in the case [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software [3]. Law Firm Background - The Gross Law Firm is recognized for its commitment to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].